| human | Q5 |
| P2456 | DBLP author ID | 69/3926 |
| P496 | ORCID iD | 0000-0002-6456-7730 |
| P108 | employer | French National Institute of Health and Medical Research | Q1474517 |
| P735 | given name | Bruno | Q1874605 |
| Bruno | Q1874605 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q38758481 | A Cell-Penetrating Peptide Targeting AAC-11 Specifically Induces Cancer Cells Death. |
| Q40343332 | A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells |
| Q112643710 | A new ChEMBL dataset for the similarity-based target fishing engine FastTargetPred: Annotation of an exhaustive list of linear tetrapeptides |
| Q33379337 | A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity |
| Q41511323 | AMMOS2: a web server for protein-ligand-water complexes refinement via molecular mechanics |
| Q28474233 | AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening |
| Q48876534 | Acute genetic ablation of pendrin lowers blood pressure in mice. |
| Q40138033 | Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group |
| Q46815143 | An exploration of the 3D chemical space has highlighted a specific shape profile for the compounds intended to inhibit protein-protein interactions. |
| Q24645042 | Analysis of binding sites on complement factor I that are required for its activity |
| Q42141370 | Analysis of binding sites on complement factor I using artificial N-linked glycosylation |
| Q89874776 | Analysis of protein missense alterations by combining sequence- and structure-based methods |
| Q93345979 | Analysis of solvent-exposed and buried co-crystallized ligands: a case study to support the design of novel protein-protein interaction inhibitors |
| Q89601782 | Anti-Factor B Antibodies and Acute Postinfectious GN in Children |
| Q37705854 | Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes. |
| Q48539615 | Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10. |
| Q60250460 | Characterization of the complement inhibitory function of Rhesus rhadinovirus |
| Q40029426 | Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). |
| Q27010681 | Chemical libraries dedicated to protein-protein interactions |
| Q35741515 | Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? |
| Q38950578 | Computational Biology and Chemistry in MTi: Emphasis on the Prediction of Some ADMET Properties. |
| Q38732067 | Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors |
| Q38377610 | Computational investigations of hERG channel blockers: New insights and current predictive models |
| Q30884784 | DG-AMMOS: a new tool to generate 3d conformation of small molecules using distance geometry and automated molecular mechanics optimization for in silico screening |
| Q38908172 | DNA damage-induced nuclear translocation of Apaf-1 is mediated by nucleoporin Nup107. |
| Q35921636 | Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V |
| Q28473098 | Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods |
| Q33408602 | Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors |
| Q38884302 | Discoidin Domains as Emerging Therapeutic Targets. |
| Q52651324 | Discovery of novel inhibitors of vascular endothelial growth factor-A-Neuropilin-1 interaction by structure-based virtual screening. |
| Q33649365 | Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery |
| Q48159506 | Expression and functional characterization of two natural heparin-binding site variants of antithrombin. |
| Q33371792 | FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects |
| Q35604907 | FAF-Drugs3: a web server for compound property calculation and chemical library design. |
| Q47317732 | FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery |
| Q98391929 | Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein-Protein Interfaces |
| Q34662757 | Free resources to assist structure-based virtual ligand screening experiments |
| Q33420841 | Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients |
| Q35793072 | Functions of human complement inhibitor C4b-binding protein in relation to its structure |
| Q36546628 | Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia |
| Q28303343 | Genetic, molecular and functional analyses of complement factor I deficiency |
| Q89800911 | Gly197Arg mutation in protein C causes recurrent thrombosis in a heterozygous carrier |
| Q35037859 | Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins |
| Q35165195 | Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737. |
| Q47161167 | Identification of insulin-sensitizing molecules acting by disrupting the interaction between the Insulin Receptor and Grb14. |
| Q35090048 | Identification of novel small molecule inhibitors of activated protein C. |
| Q35573183 | In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances |
| Q28536904 | In silico mechanistic profiling to probe small molecule binding to sulfotransferases |
| Q41243043 | In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
| Q37677338 | In silico studies of blood coagulation proteins: from mosaic proteases to nonenzymatic cofactor inhibitors |
| Q37130829 | In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics |
| Q28534051 | Insights into an original pocket-ligand pair classification: a promising tool for ligand profile prediction |
| Q55421031 | Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9*30. |
| Q30378479 | Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6. |
| Q36564330 | Kaposi's sarcoma-associated herpes virus complement control protein: KCP--complement inhibition and more |
| Q27690213 | Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches |
| Q33385907 | MED-3DMC: a new tool to generate 3D conformation ensembles of small molecules with a Monte Carlo sampling of the conformational space |
| Q33283556 | MED-SuMoLig: a new ligand-based screening tool for efficient scaffold hopping |
| Q33327574 | MS-DOCK: accurate multiple conformation generator and rigid docking protocol for multi-step virtual ligand screening |
| Q35597960 | MTiOpenScreen: a web server for structure-based virtual screening. |
| Q113308777 | Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9 |
| Q40422254 | Mapping of the factor Xa binding site on factor Va by site-directed mutagenesis |
| Q44534312 | Mutations in alpha-chain of C4BP that selectively affect its factor I cofactor function |
| Q28263131 | Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I |
| Q28267924 | Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome |
| Q28167994 | Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke |
| Q38119805 | One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade |
| Q24812137 | PCE: web tools to compute protein continuum electrostatics |
| Q88446699 | Pan-assay interference compounds (PAINS) that may not be too painful for chemical biology projects |
| Q38969903 | Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. |
| Q79100949 | Probing plasma clearance of the thrombin–antithrombin complex with a monoclonal antibody against the putative serpin–enzyme complex receptor‐binding site |
| Q28293819 | Proposed structural models of the prothrombinase (FXa-FVa) complex |
| Q30368994 | Protein structure analysis online. |
| Q30962611 | Rationalizing the chemical space of protein-protein interaction inhibitors |
| Q33262082 | Receptor-based computational screening of compound databases: the main docking-scoring engines |
| Q36110345 | Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition |
| Q90858094 | Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type Amino acid Transporter 1 (LAT1) |
| Q60250710 | Role of CCP2 of the C4b-binding protein β-chain in protein S binding evaluated by mutagenesis and monoclonal antibodies |
| Q36944104 | Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-actions Through Structure-Based Virtual Ligand Screening Experiments. |
| Q34790625 | Structural bioinformatics: methods, concepts and applications to blood coagulation proteins. |
| Q56895697 | Structural requirements of anticoagulant protein S for its binding to the complement regulator C4b-binding protein |
| Q36526549 | Structural stability and heat-induced conformational change of two complement inhibitors: C4b-binding protein and factor H |
| Q98171425 | Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages |
| Q33285015 | Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections |
| Q37660412 | Structure-based virtual ligand screening: recent success stories |
| Q34111157 | Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening |
| Q39672653 | Tensin2 reduces intracellular phosphatidylinositol 3,4,5-trisphosphate levels at the plasma membrane |
| Q33920633 | The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections |
| Q51810670 | The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2. |
| Q45013859 | The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system |
| Q38287370 | The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody |
| Q36156027 | The anticoagulant protein C pathway |
| Q35462720 | Theileria parasites secrete a prolyl isomerase to maintain host leukocyte transformation |
| Q35620775 | Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors. |
| Q37953143 | Toward in silico structure-based ADMET prediction in drug discovery. |
| Q28478649 | Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening |
| Q90428394 | Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace |
| Q33631088 | Zebrafish ProVEGF-C expression, proteolytic processing and inhibitory effect of unprocessed ProVEGF-C during fin regeneration |
| Q38108039 | iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions |
| Q36435078 | iPPI-DB: an online database of modulators of protein-protein interactions. |
Search more.